Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P120008/S032

ARCHITECT AFP; Alinity i AFP (LN 3P36/07P90)

ABBOTT LABORATORIES · Decision date May 11, 2026

FDA DECISIONP120008/S032

What did the FDA decide?

FDA records P120008/S032 as a supplement to PMA P120008, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated May 11, 2026.

FDA approval order statement

Approval of changes in testing requirements of reference materials.
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Immunology
Decision date
May 11, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P120008/S032
Regulatory pathway
PMA supplement
Product code
LOK
Decision code
OK30
Decision date
May 11, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: KIT, TEST, ALPHA-FETOPROTEIN FOR NEURAL TUBE DEFECTS.

Product code
LOK
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P120008/S031 · Related supplement

    ARCHITECT AFP; Alinity i AFP (LN 3P36/07P90)

  2. P120008/S032 received

    Application receipt date recorded by FDA.

  3. P120008/S032 · FDA decision

    30-Day Notice

Timeline entries are records held by MedtechLedger for P120008. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P120008

Product / regulatory recordCompanyPathwayDecision dateSource
ABBOTT LABORATORIESPMA supplementFeb 12, 2026FDA

Explore the linked device profile

Other records with product code LOK

Product / regulatory recordCompanyPathwayDecision dateSource
Siemens Healthcare Diagnostics, Inc.PMA supplementSep 22, 2026FDA
Siemens Healthcare Diagnostics, Inc.PMA supplementAug 20, 2026FDA
IMMULITE 2000 AFPP010007/S026
Siemens Healthcare Diagnostics, Inc.PMA supplementJul 27, 2026FDA
Siemens Healthcare Diagnostics, Inc.PMA supplementMay 11, 2026FDA
IMMULITE 2000 AFPP010007/S025
Siemens Healthcare Diagnostics, Inc.PMA supplementApr 21, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

ABBOTT LABORATORIES

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
09v6 Ap5-2n, 100 Abbott Park Rd., Abbott Park, IL, 60064

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records